Pharmacology of new aromatase inhibitors

Breast

Volumn 5, Issue 3, 1996, Pages 202-208

  Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; FADROZOLE; FORMESTANE; LETROZOLE; PYRIDOGLUTETHIMIDE;

AROMATIZATION; BREAST CANCER; CONFERENCE PAPER; CROSS RESISTANCE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030057071     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90094-6     Document Type: Conference Paper

References (45)

1. Huggins C, Dao TL-Y. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA 1953; 151: 1388-1394.
2. Luft R, Olivecrona H, Sjögren B. Hypofysektomi på människa. Nor Med 1952; 14: 351-354.
3. Lønning P E, Dowsett M, Powles T J. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990; 5: 355-366.
4. Lønning P E, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35: 685-710.
5. Samojlik E, Santen R J, Wells S A. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J Clin Endocrinol Metab 1977; 45: 480-487.
6. Santen R J, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257-1265.
7. Coombes R C, Goss P, Dowsett M, Gazet J-C, Brodie A. 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984; ii: 1237-1239.
8. Santen R J, Worgul T J, Lipton A, Harvey H, Boucher A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982; 96: 94-101.
9. Dowsett M, Cunningham D C, Stein R C et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306-1312.
10. Dowsett M, Stein R C, Mehta A, Coombes R C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 1990; 32: 623-634.
11. Reed M J, Owen A M, Lai L C et al. In situ oestrone synthesi in normal breast and breast tumour tissue: effect of treatment with 4-hydroxyandrostenedione. Int J Cancer 1989; 44: 233-237.
12. Miller W R. Importance of intratumour aromatase, and its susceptibility to inhibitors. In: Dowsett M, ed. Aromatase inhibition - then, now and tomorrow. London: Partenon Publishing Group, 1994.
13. Lønning P E, Skulstad P, Sunde A, Thorsen T. Separation of urinary metabolites of radiolaballed estrogens in man by HPLC. J Steroid Biochem 1989; 32: 91-97.
14. Jacobs S, Lønning P E, Haynes B, Griggs L, Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhibition 1991; 4: 315-325.
15. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith I E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-1515.
16. MacNeill F A, Jones A L, Jacobs S, Lønning P E, Powles T J, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992; 66: 692-697.
17. Jones A L, MacNeill F, Jacobs S, Lønning P E, Dowsett M, Powles T J. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992; 28A: 1712-1716.
18. MacNeill F A, Jacobs S, Dowsett M, Lønning P E, Powles T J. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 1995; 36: 249-254.
19. MacNeill F A, Jacobs S, Lønning P E, Powles T J, Dowsett M. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and estrogen suppression. Br J Cancer 1994; 69: 1171-1175.
20. Lønning P E, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991; 63: 789-793.
21. Geisler J, Lønning P E, Dowsett M et al. A randomised, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by arimidex (ZD 1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer. The Breast 1995; 4: 227.
22. Lønning P E, Helle S I, Johannessen D C et al. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clin Endocrinol 1995; 42: 23-30.
23. Iveson T J, Smith I E, Ahem J, Smithers D A, Trunet P F, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77: 324-331.
24. Johnston SRD, Smith I E, Doody D, Jacobs S, Robertshaw H, Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 1994; 54: 5875-5881.
25. Lønning P E, Johannessen D C, Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989; 60: 107-111.
26. Lønning P E, Ekse D. A sensitive assay for measurement of plasma oestrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Molec Biol 1995; 55: 409-412.
27. Demers L M. Effects of fadrozole (COS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994; 30: 95-102.
28. Geisler J, Johannessen D C, Anker G, Lønning P E. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. Eur J Cancer. In press.
29. Lønning P E. New endocrine drugs for treatment of advanced breast cancer. Acta Oncol 1990; 29: 379-386.
30. Bonneterre J, Coppens H, Mauriac L et al. Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomised trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 1985; 21: 1153-1158.
31. Bruning P F, Bonfrer JMG, Hart A A M et al. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 1989; 25: 369-376.
32. Strocchi E, Camaggi C M, Martoni A et al. Aminoglutethimide in advanced breast cancer: Plasma levels and clinical results after low and high dose. Cancer Chemother Pharmacol 1991; 27:451-455.
33. Robustelli GdC. 500 mg versus 1000 mg aminoglutethimide (AG) in advanced breast cancer: 3 years results of an Italian multicentre trial. Eur J Cancer 1991; 27 (Suppl. 2): 69.
34. Jonat W, Buzdar A, Howell A et al. Two randomised trials establishing efficacy and tolerability of arimidex (ZD 1033) in the treatment of postmenopausal women with advanced breast cancer (PABP). Eur J Cancer 1995; 31A (Suppl. 5): 76.
35. Murray R, Pitt P. Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 1985; 21: 19-22.
36. Lønning P E, Dowsett M, Jones A et al. Influence of aminoglutethimide on plasma estrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Res Treat 1992; 23: 57-62.
37. Samojlik E, Santen R J, Worgul T J. Suppression of residual estrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy. Clin Endocrinol 1984; 20: 43-51.
38. Dowsett M, Stein R C, Coombes R C. Aromatisation inhibition alone or in combination with GmRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Molec Biol 1992; 43: 155-159.
39. Murray R, Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995; 35: 249-253.
40. Bundred N J, Eremin O, Stewart H J, Dale B A, Forrest A P M. Beneficial response to pituitary ablation following aminoglutethimide. Br J Surg 1986; 73: 388-389.
41. Sourdaine P, Parker M G, Telford J, Miller W R. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol 1994; 13: 331-337.
42. Masamura S, Santner S J, Heitjan F, Santen R J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocinol Metab 1995; 80: 2918-2925.
43. Reed M J, Aherne G W, Ghilchik M W, Patel S, Chakraborty J. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. Int J Cancer 1991; 49: 562-565.
44. Van Landeghem A A J, Poortman J, Nabuurs M, Thijssen J H H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res 1985; 45: 2900-2904.
45. Simon M. Design and conduct of clinical trials. In: De Vita V T, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 1985: 329-350.